LogicBio Brings Two Gene Editing Platforms to AstraZeneca in $68 Million Deal
AstraZeneca is spending $68 million to acquire LogicBio Therapeutics, a move that brings two innovative gene editing platforms to the pharma giant’s fold. Source: Drug Industry Daily